Free Trial

Insider Selling: CeriBell, Inc. (NASDAQ:CBLL) Director Sells 11,188 Shares of Stock

CeriBell logo with Medical background

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca B. Robertson sold 11,188 shares of the stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total value of $199,705.80. Following the completion of the transaction, the director now directly owns 10,042 shares of the company's stock, valued at $179,249.70. This represents a 52.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

CeriBell Stock Up 3.2%

NASDAQ CBLL traded up $0.58 during mid-day trading on Monday, reaching $18.49. The stock had a trading volume of 318,510 shares, compared to its average volume of 282,407. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $32.75. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.36 and a quick ratio of 16.81. The company has a fifty day moving average price of $16.67 and a 200 day moving average price of $20.64.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to the consensus estimate of $19.30 million. Analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.

Hedge Funds Weigh In On CeriBell

A number of institutional investors and hedge funds have recently modified their holdings of CBLL. Rhumbline Advisers increased its position in CeriBell by 26.5% during the first quarter. Rhumbline Advisers now owns 15,629 shares of the company's stock valued at $300,000 after acquiring an additional 3,276 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of CeriBell during the 1st quarter valued at about $175,000. Lord Abbett & CO. LLC lifted its stake in shares of CeriBell by 7.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock worth $6,138,000 after purchasing an additional 23,451 shares during the period. Nuveen LLC purchased a new position in CeriBell during the first quarter valued at $311,000. Finally, Swiss National Bank purchased a new stake in CeriBell in the first quarter worth about $467,000.

Wall Street Analyst Weigh In

CBLL has been the topic of a number of analyst reports. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $32.50.

Check Out Our Latest Stock Analysis on CeriBell

CeriBell Company Profile

(Get Free Report)

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Featured Stories

Insider Buying and Selling by Quarter for CeriBell (NASDAQ:CBLL)

Should You Invest $1,000 in CeriBell Right Now?

Before you consider CeriBell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.

While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines